Our fees are changing on 4 March 2023. Learn more.


A round-head red mushroom growing in the wild with leaves underneath.
Share

Flesh of the Gods

Possibly the world’s oldest drug, magic mushrooms or shrooms are about to hit the mainstream. No, they’re not becoming legal (yet) but rather the U.S. Federal government has granted researchers funding to study the benefits of psilocybin, the primary psychoactive ingredient in shrooms.

More specifically, the US$4m grant by the National Institutes of Health (NIH) will go towards assessing mushrooms’ impact on helping people quit smoking. But that’s also what vapes claim to solve, so what other benefits are there, apart from boosting the enjoyment of a rave? 

Well, apparently a lot. Psychedelics reportedly help treat depression and even manage alcohol addiction. And despite the U.S. government ceasing funding into psychedelics back in 1970, more research continues to come out as the private sector didn’t get the memo. Data Bridge Market Research estimates the global pharmaceutical psilocybin market will reach US$6.9b by 2027. 

Here are two examples of existing trials. St Vincent’s Hospital in Sydney trialing the use of psilocybin to stop or reduce methamphetamine use. And Compass Pathways’ (NASDAQ: CMPS) has COMP360, a psilocybin therapy being tested for use in treatment-resistant depression, post-traumatic stress disorder, and major depressive disorder.

Shrooms are breaking into the cultural mainstream lately, with Harry Styles claiming they boosted his creativity and Joe Rogan infamously using them to record a 3.5 hour podcast with Post Malone. Now it’s the scientific community getting onboard with the growing belief that mushrooms might just be one of the next great wonder drugs. 


Don’t have Stake?

Get $10 when you fund Stake AUS, a free US stock when you fund Stake Wall St. Do both, get both!


Related


Stake logo
Download Stake
App Store logo
Google Play logo

Stakeshop Pty Ltd is registered as an overseas company in New Zealand (NZBN: 9429047452152), and is registered as a Financial Service Provider under the Financial Service Providers (Registration and Dispute Resolution) Act 2008 (No. FSP774414). We hold a full licence issued by the Financial Markets Authority to provide a financial advice service under the Financial Markets Conduct Act 2013. However, the content on this website has not been prepared to take into account any of your individual objectives, financial situation or needs. To the extent you require further information about the relevant New Zealand legislation that may apply, or require specific advice, please contact your legal and/or financial adviser (as appropriate). The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Terms & Conditions, Privacy Policy, Financial Advice Disclosure and Disclaimers before deciding to use or invest on Stake. By using the Stake website or service in any way, you agree to our Privacy Policy and Terms & Conditions All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake is a registered trademark under class 36 (New Zealand).

Copyright © 2023 Stake. All rights reserved.